Business
Vistagen to Present at the 2025 Anxiety and Depression Association Conference
SOUTH SAN FRANCISCO, Calif., March 19, 2025--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present at the Anxiety and Depression Association of America (ADAA) Conference in Las Vegas, Nevada from April 3 to 5, 2025. The Company’s poster presentations will explore the age of onset of social anxiety disord
About this update from Vistagen Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2000,"height":542,"url":"https://media.zenfs.com/en/business-wire.com/d54993bc044a83d6c1aca426594f9056"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/M4_c7gRzgGks9ysikO8uLA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d54993bc044a83d6c1aca426594f9056","width":960,"height":260},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/snTrE.bqvY3.4G8h_Tta_w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02NTA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/d54993bc044a83d6c1aca426594f9056","width":1200,"height":325}},"lazy":false},{"type":"text","content":"Posters Highlight New Insights into Social Anxiety Disorder","length":59,"tagName":"p","attribs":{}},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., March 19, 2025--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present at the Anxiety and Depression Association of America (ADAA) Conference in Las Vegas, Nevada from April 3 to 5, 2025. The Company’s poster presentations will explore the age of onset of social anxiety disorder (SAD) from participants in fasedienol clinical trials, and new data on the characteristics of young adults with and without SAD.","length":648,"tagName":"p"},{"type":"text","content":"Poster Presentations:Date: Friday, April 4, 2025, 5:00 p.m. Eastern TimeTitle: Age of Onset of Social Anxiety Disorder (SAD) in Trials of Fasedienol (PH94B) Nasal SprayAuthors: Ester Salmán, MPH; Ross A. Baker, PhD; Stephen D. Coffey, BA; Rita Hanover, PhD; Michael R. Liebowitz, MD, and Louis Monti, MD, PhDPoster Number: F40","length":330,"tagName":"p"},{"type":"text","content":"Date: Saturday, April 5, 2025, 5:00 p.m. Eastern TimeTitle: Social Anxiety Disorder among Young Adults (18 – 22 years): A Cross-Sectional Study Using Data from the US National Health and Wellness SurveyAuthors: Ross A. Baker, PhD; Josh Prince; Nikoletta Sternbach; Soohyun Hwang, PhD, MPHPoster Number: S109","length":310,"tagName":"p"},{"type":"text","content":"These posters will be available on the Publication...